FundingChina

MegaRobo raises nearly $200M for AI-run labs as Oman's wealth fund joins

Published 2 min read
Source
MegaRobo raises nearly $200M for AI-run labs as Oman's wealth fund joins (Illustration by MEKAWIRE)

MegaRobo Technologies, a Chinese maker of AI-run automated laboratories, said on Nov 18, 2026 that it raised nearly USD 200 million in a new round joined by Oman Investment Authority, with existing investors Asia Investment Capital, Granite Asia and Sinovation Ventures and new investor CMB International.

Its release says it has delivered products to more than 500 customers, its website lists 880+ clients, and it has raised about USD 600 million in total. No lead investor, round letter or valuation was disclosed.

MegaRobo Technologies, a Chinese company that builds automated laboratories run by AI software, said in a press release datelined Suzhou on Nov 18, 2026 that it had raised nearly USD 200 million in a new financing round. Oman Investment Authority, the sovereign wealth fund of Oman, joined the round. Existing investors Asia Investment Capital, Granite Asia and Sinovation Ventures invested again and CMB International came in as a new investor. The release did not name a lead investor, a round letter or a valuation.

What the money buys: lab robots that take orders from software

MegaRobo calls its underlying technology architecture a "One Intelligence Stack": models and agents, data, workflow software, scientific instruments and robotic automation joined in one system, so that an AI can design an experiment, run it on real equipment, read the result and choose the next step. The release says it has delivered products to more than 500 customers, including pharmaceutical groups, drug discovery firms, biotech companies and research institutes; its website lists 880+ clients. Its Megalaxy Lab, where researchers or AI agents submit experiments that automated lab systems execute and return as machine-readable data, has served more than 200 customers, according to the release.

The new money will support core technology, the global expansion of its AI for Science business and infrastructure for AI that works in physical environments, the company said. In October it launched Poreva Open, a protein design competition supported by Tencent Cloud and Twist Bioscience, among others; the organisers plan to test more than 10,000 selected designs in the wet lab at Megalaxy Lab.

How the round compares

MegaRobo and selected 2026 robotics rounds
  • MegaRobo
    Country
    CN
    Round
    New round (letter not disclosed)
    Announced
    Nov 18, 2026
    Amount (USD)
    nearly 200M
  • D-Robotics
    Country
    CN
    Round
    Series C
    Announced
    Sep 2026
    Amount (USD)
    400M
  • Opentrons
    Country
    US
    Round
    Series E
    Announced
    Oct 29, 2026
    Amount (USD)
    40M

MegaRobo: company release of Nov 18, 2026. Others: MEKAWIRE funding records, as of Nov 20, 2026; disclosed amounts only.

As of Nov 20, 2026

MegaRobo says it has raised about USD 600 million in total. The release describes its Series C, co-led by Goldman Sachs Alternatives, Asia Investment Capital and Granite Asia, as nearly USD 300 million; the Hong Kong listing application MegaRobo filed in June 2025 records USD 255 million paid for Series C shares and disclosed 2024 revenue of RMB 929.6 million. By MEKAWIRE calculation, the new round is roughly a third of that total and about five times the USD 40 million Series E that US lab-robot maker Opentrons announced on Oct 29. Earlier industry investors named in the release include WuXi AppTec and Bosch Ventures.

MEKAWIRE analysis

MegaRobo is selling lab capacity as a service that software can call, and the round tests whether investors value that as infrastructure rather than as lab automation equipment.

The bull case is that drug developers and AI model makers need experimental data at a volume human labs cannot supply, and a company that lists more than 880 clients already has the installed base. The bear case is that the business still leans on China: DealStreetAsia reported that about 80% of revenue is domestic, and the funding release names no valuation and no overseas customer. Signals to watch are any Middle East project involving the Omani fund, Poreva Open results and an updated listing filing with newer financials.

Good or bad news for the company?

 

Key facts
Amount
Nearly USD 200M, announced Nov 18, 2026
Customers
880+ on company website; 500+ in the release
2024 revenue
RMB 929.6M (HKEX listing application)
Megalaxy Lab
More than 200 customers (company)
New investors
Oman Investment Authority, CMB International
Raised to date
About USD 600M (company)
Earlier Series C
Nearly USD 300M per release; USD 255M paid per June 2025 HKEX filing
Returning investors
Asia Investment Capital, Granite Asia, Sinovation Ventures
Round size vs Opentrons Series E
About 5x (MEKAWIRE calc.)
Sources